Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ATP4A | P20648 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ATP4B | P51164 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL27313058 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL3735476 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28681657 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL226031 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL1736444 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28666399 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28492534 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL1736443 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL22127097 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28689625 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| EP-4360512-B1 | TRANSPORT PACKAGE FOR NEEDLED CHRISTMAS TREES | VERWEYEN SEBASTIAN (DE) | 2025-06-25 | — | — | EP | claimed |
| EP-4295670-B1 | DEVICE FOR FIXING A IRRIGATION CANE FOR IRRIGATING TREE CROPS | DESIGN AND PRINT 3D (FR) | 2025-04-30 | — | — | EP | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-114763335-B | 4-Amide piperidine derivative and preparation method and application thereof | 江苏谛奇医药科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-115379759-B | Method for controlling pests, pest control agent composition, and pest control agent set | 日本曹达株式会社 | 2025-03-14 | — | — | CN | claimed |
| US-12206795-B2 | Lightweight attribute-based signcryption (ABSC) method for cloud-fog-assisted internet-of-things (IoT) | QILU UNIVERSITY OF TECHNOLOGY (CN) | 2025-01-21 | — | — | US | claimed |
| CN-119300838-A | Oligosaccharide linker, linker-cargo comprising oligosaccharide linker and antibody conjugated drug with sugar chain remodelling, preparation method and use thereof | 启德医药科技（苏州）有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119232722-A | System and method for micro-service cross-region registration and call | 许继电气股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119231643-A | Distributed light Fu Qun group control method | 国网天津市电力公司 | 2024-12-31 | — | — | CN | claimed |
| EP-0367484-B1 | Carboxylic acid derivates | GLAXO GROUP LTD (GB) | 1994-02-16 | — | — | EP | claimed |
| EP-0279161-B1 | A process for the preparation of cimetidine | LEK TOVARNA FARMACEVTSKIH (SI) | 1994-01-05 | — | — | EP | claimed |
| EP-0571463-A1 | NOVEL CIMETIDINE POLYMORPH AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1993-12-01 | — | — | EP | claimed |
| WO-1992014713-A1 | NOVEL CIMETIDINE POLYMORPH AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1992-09-03 | — | — | WO | claimed |
| EP-0261818-B1 | PROCESS FOR PREPARATION OF GUANIDINE DERIVATIVE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-11 | — | — | EP | claimed |
| US-4973703-A | ACTIVATED CARBON IN WATER IN PRESENCE OR ORGANIC ACID | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-11-27 | — | — | US | claimed |
| US-4808726-A | REACTING N-CYANO-N*-METHYL-N\"-(2-(BUTANE-2,3-DIONYL) THIOETHYL) GUANIDINE WITH AMMONIUM SALT OF A CARBOXYLIC ACID AND FORMALDEHYDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-28 | — | — | US | claimed |
| EP-0261818-A1 | Process for preparation of guanidine derivative | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-30 | — | — | EP | claimed |
| EP-0224612-A1 | Process for the preparation of N-cyano-N'-methyl-N''[2-(5-methylimidazol-4-ylmethylthio)-ethyl]-guanidine | HEUMANN PHARMA GMBH & CO (DE) | 1987-06-10 | — | — | EP | claimed |
| EP-0046290-B1 | SYNERGISTIC COMBINATION OF (R,S)ALPHA-FLUOROMETHYLHISTIDINE AND CIMETIDINE AS AN ANTI-ULCER AGENT | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | GCG, VAPA, GABRG2 | HRH2 2029/4885CYP3A4 1107/4885CYP2D6 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.